




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

Indian Journal of Medical Microbiology

journal homepage: www.journals.elsevier.com/indian-journal-of-medical-microbiology

Brief Communication

A retrospective analysis of COVID-19 diagnosis results obtained by rapid antigen tests and RT-PCR: Implications for disease management



Kiran Munne^a, Venkanna Bhanothu^b, Anjali Mayekar^c, Shantanu Birje^c, Vikrant Bhor^d, Vainav Patel^e, Smita D. Mahale^f, Shailesh S. Pande^{g,*}

^a Scientist-B, Department of Clinical Research, ICMR-National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, 400012, India

^b Scientist-B, Genetic Research Centre, ICMR-National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, 400012, India

^c Department of Clinical Research, ICMR-National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, 400012, India

^d Scientist-D, Department of Molecular Immunology and Microbiology, ICMR-National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, 400012, India

^e Scientist-E, Department of Biochemistry, ICMR-National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, 400012, India

^f ICMR-National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, 400012, India

^g Scientist-D, Genetic Research Centre, ICMR-National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai, 400012, India

ARTICLE INFO

Keywords:

COVID-19

Rapid antigen testing (RAT)

RT-PCR

SARS-CoV-2

ABSTRACT

There is a need for understanding and establishment of the most appropriate testing algorithm for COVID-19 diagnosis in asymptomatic high-risk groups. Here, we present a retrospective analysis of RT-PCR results obtained from 412 cases tested negative for coronavirus disease 2019 (COVID-19) by rapid antigen testing method. Among 178 (43.2%) asymptomatic individuals, 44.9% of the high risk contacts, 12.2% of police custody individuals, 22.22% of the pregnant women and 33.33% of individuals hospitalised for preoperative or other medical conditions showed RT-PCR positivity. Our results suggest a need for focussed and intensive (multi-modality) testing in groups at high risk for SARS-CoV-2 infection.

1. Introduction

Several screening and confirmatory tests are available for the detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1–3]. Screening tests like rapid antigen test (RAT) can identify the population at high risk [4]. Though, RAT has lower sensitivity, is comparatively cost-effective, rapidly deployable and faster [1]. RAT reduces the dependence on real time reverse transcriptase polymerase chain reaction (RT-PCR), where cost of the RT-PCR kits and technical expertise are major concerns [5]. RAT is helpful if done at early stage of infection where viral load is high. Such individuals if isolated faster can limit the disease spread [1]. However, antigen levels may drop below the limit of detection in specimens collected beyond 5–7 days of onset of the symptoms [6].

Since, screening by RAT is associated with false negative results, RT-PCR still remains the “gold standard” for diagnosis of SARS-CoV-2 infection as it detects pathogen based on amplification of target genes using specific primers [5,7]. It is an accurate, reliable and more sensitive

method. As per guidelines, suspected cases with antigen negative reports need to be further evaluated with RT-PCR and the interval between collection of samples for the two tests should be less than two days [6,8].

2. Methods

Here, we present a retrospective analysis of RT-PCR results obtained from 412 cases tested negative for coronavirus disease 2019 (COVID-19) by RAT. All cases were referred from Municipal Corporations and Government hospitals of Mumbai and its periphery, during 7th July - 7th August 2020 to COVID-19 testing laboratory at ICMR-NIRRH, Mumbai. RAT data and characteristics of patients like age, gender, clinical presentations and underlying medical conditions were extracted from ICMR Specimen Referral Form (SRF) for COVID-19. All samples were processed for RNA extraction and analysed by various RT-PCR platforms and kits. The testing was done as per the manufacturer's protocol.

* Corresponding author.

E-mail addresses: munek@nirrh.res.in (K. Munne), bhanothuv@nirrh.res.in (V. Bhanothu), mayekar_a@yahoo.in (A. Mayekar), shantanubirje01@gmail.com (S. Birje), bhorv@nirrh.res.in (V. Bhor), patelv@nirrh.res.in (V. Patel), smitamahale@hotmail.com (S.D. Mahale), pandes@nirrh.res.in (S.S. Pande).

<https://doi.org/10.1016/j.ijmmb.2021.05.006>

Received 28 November 2020; Received in revised form 9 April 2021; Accepted 6 May 2021

Available online 25 May 2021

0255-0857/© 2021 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.

Table 1

RT-PCR outcomes among asymptomatic and symptomatic antigen negative tested COVID-19 cases.

RT-PCR results	Asymptomatic	Symptomatic (N = 234)	
	N = 178 (100%)	Multiple symptoms N = 190 (100%)	Single symptom N = 44 (100%)
Positive	48 (26.9)	74 (38.9)	17 (38.64)
Negative	125 (70.2)	104 (54.74)	27 (61.36)
Inconclusive	5 (2.81)	12 (6.31)	Nil

Abbreviations: N, number, %, percentage.




Fig. 1. Distribution of asymptomatic rapid antigen test negative cases and their RT-PCR outcomes (N=178) as positive, negative and inconclusive for different sub-groups.

3. Results

Out of 412 RAT negative samples, 139 (33.7%) were positive, 256 (62.14%) were negative and 17 (4.13%) were inconclusive by RT-PCR. Of these 412 RAT negative cases, 234 were symptomatic and 178 were asymptomatic (Table 1). The latter include, individuals undergoing antenatal visits, surgery and those who were high-risk contacts. Of the 234 symptomatic patients 91(38.8%) showed positivity, 131(55.55%) showed negativity and 12(5.1%) were inconclusive on RT-PCR. The samples reported initially inconclusive by RT-PCR were repeated and 17 (4.13%) of which remained inconclusive after retesting. The percentage of positivity in RT-PCR was similar (38.9% and 38.64%) in individuals with single or multiple symptoms. Of the 178 asymptomatic individuals negative for RAT, 48 (26.96%) were positive, 125 (70.22%) were negative and 5 (2.81%) were inconclusive on RT-PCR. Of these, 49 (27.5%) were high risk contacts of confirmed case of COVID-19, 57 (32%) were from police custody, 36 (20.2%) were pregnant women, 3 (1.69%) were newborns and 33 (18.53%) were admitted preoperative or for other medical conditions. The RT-PCR outcome for these asymptomatic groups is shown in Fig. 1.

In older age group (61–80 years) around 46% of RAT negative cases were positive by RT-PCR (Supplementary Fig. 1). Among 412 RAT negative cases, 89 (21.6%) had pre-existing comorbidities like diabetes, hypertension, cardiovascular disease, chronic renal disease, malignancy etc. Out of them, 32 (35.95%) individuals were positive by RT-PCR.

4. Discussion

In the retrospective analysis of RT-PCR data of 412 RAT negative cases, 139 (33.7%) were positive by RT-PCR, maybe because of lower sensitivity of RAT. As per the literature, the percentage of false negative SARS-CoV-2 result is high in RAT [6,9]. A study reported 89.9% (95% CI 85.4%–94.4%) of sensitivity and 97.6% (95% CI 96.5%–98.5%) of specificity by RAT in symptomatic patients, whereas, only 50.0% (95% CI

36.0%–63.0%) of sensitivity and 99.6% (95% CI 99.1%–99.9%) of specificity in asymptomatic individuals [10]. 234 (56.8%) of RT-PCR positive individuals were symptomatic in the form of fever, sore throat, breathlessness, cough, body ache, diarrhoea and vomiting. Out of 178 asymptomatic patients showing negative RAT results, 48 (26.96%) were positive on RT-PCR. Both tests in 46 out of these 48 individuals were carried out on the same day, ruling out the possibility of RT-PCR positivity following post RAT infection. The impact of SARS-CoV-2 infection is more with co-morbidities, elderly, pregnant women etc. [11,12] In our study, among 44.9% of the high risk contacts, 12.2% of police custody individuals, 22.22% of the pregnant women and 33.33% of individuals hospitalised for preoperative or other medical conditions showed RT-PCR positivity.

There is limited data on usage of RAT in asymptomatic individuals to detect or exclude COVID-19, or to determine infectious status of previously confirmed cases [6]. In our study, the date of onset of symptoms was not known in many cases as it was not a mandatory field in the ICMR specimen referral form. However, the date of RAT and collection of the sample for RT-PCR was the same. Hence comparison of these are possible. Moreover, the RAT for COVID-19 showed lower sensitivity than RT-PCR test both for symptomatic (single or multiple symptoms) and asymptomatic infection. Confirmation of antigen negative tested individuals by RT-PCR especially for asymptomatic or high-risk groups is critical for prompt isolation and clinical management. Our results suggest need for focussed and intensive (multi-modality) testing in groups at high risk for SARS-CoV-2 infection and strongly support the use of RT-PCR as the first line of testing instead of RAT in asymptomatic high-risk group.

Financial Support and sponsorship

Not Applicable.

Conflicts of interest

There are no conflicts of interest.

CRediT authorship contribution statement

Kiran Munne: Concepts, Design, Definition of intellectual content, Literature search, Funding acquisition, Data acquisition, Statistical analysis, Writing – original draft, Manuscript preparation. **Venkanna Bhanothu:** Concepts, Design, Definition of intellectual content, Literature search, Funding acquisition, Data acquisition, Data curation, Formal analysis, Data analysis, Statistical analysis, Writing – original draft, Manuscript preparation. **Anjali Mayekar:** Design, Definition of intellectual content, Literature search, Funding acquisition, Data acquisition, Data curation, Formal analysis, Data analysis, Writing – original draft, Manuscript preparation. **Shantanu Birje:** Data curation, Formal analysis, Data analysis. **Vikrant Bhor:** Data curation, Formal analysis, Data analysis. **Vainav Patel:** Definition of intellectual content, Writing – review & editing, Manuscript editing. **Smita D. Mahale:** Definition of intellectual content, Writing – review & editing, Manuscript editing, Manuscript review. **Shailesh S. Pande:** Concepts, Design, Definition of intellectual content, Writing – original draft, Manuscript preparation, Writing – review & editing, Manuscript editing, Manuscript review, Guarantor.

Acknowledgement

We acknowledge the encouragement and support from Director General, Indian Council of Medical Research (ICMR), Ministry for Health & Family Welfare, Government of India.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://>

doi.org/10.1016/j.ijmmb.2021.05.006.

References

- [1] Indian Council of Medical Research (Icmr). Advisory on use of rapid antigen detection test for COVID-19. Available at: https://www.icmr.gov.in/pdf/covid/strategy/Advisory_for_rapid_antigen_test14062020.pdf. [Accessed 15 September 2020].
- [2] Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 2020;26(6):845–8. <https://doi.org/10.1038/s41591-020-0897-1>.
- [3] Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. *J Am Med Assoc* 2020;323(22):2249–51. <https://doi.org/10.1001/jama.2020.8259>.
- [4] Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, et al. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. *Int J Infect Dis: IJID: official publication of the International Society for Infectious Diseases* 2020;99:328–33. <https://doi.org/10.1016/j.ijid.2020.05.098>.
- [5] Bustin SA, Nolan T. rt-qPCR testing of SARS-CoV-2: a primer. *Int J Mol Sci* 2020; 21(8):3004. <https://doi.org/10.3390/ijms21083004>.
- [6] Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): interim guidance for rapid antigen testing for SARS-CoV-2. Available at: www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html. [Accessed 15 October 2020].
- [7] Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, et al. Assay techniques and test development for COVID-19 diagnosis. *ACS Cent Sci* 2020;6(5):591–605. <https://doi.org/10.1021/acscentsci.0c00501>.
- [8] World Health Organization (Who). Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance 11 September 2020. Available at: [WHO-2019-nCoV-Antigen_Detection-2020.1-eng.pdf](https://www.who.int/docs/default-source/coronavirus/interim-guidance-11-september-2020-antigen-detection-2020-1-eng.pdf?sfvrsn=1). [Accessed 21 October 2020].
- [9] Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J Clin Virol* 2020;129:104500. <https://doi.org/10.1016/j.jcv.2020.104500>.
- [10] Turcato G, Zaboli A, Pfeifer N, et al. Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: a preliminary report. *J Infect* 2021;82(3): e14–6. <https://doi.org/10.1016/j.jinf.2020.12.012>.
- [11] Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J* 2020;55(5):2000547. <https://doi.org/10.1183/13993003.00547-2020>.
- [12] Lopes de Sousa ÁF, Carvalho HEF, Oliveira LB, et al. Effects of COVID-19 infection during pregnancy and neonatal prognosis: what is the evidence? *Int J Environ Res Publ Health* 2020;17(11):4176. <https://doi.org/10.3390/ijerph17114176>.